The Latest Cardiac and Vascular News
MUNICH–(BUSINESS WIRE)–Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced results from two prespecified analyses from the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial. The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of […]
INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency BASKING RIDGE, N.J. & SHIRLEY, N.Y.–(BUSINESS WIRE)–Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration […]
Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO®▼ in Europe, reduces the risk of serious cardiovascular (CV) events in patients with, or who are at, high risk for atherosclerotic cardiovascular disease (ASCVD) with elevated LDL-C levels1,2 The results position bempedoic acid as the […]
Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1,2,3 Latest findings presented at the European Society of Cardiology (ESC) Congress 2022 add to the wealth of edoxaban data reinforcing its safety and […]
Latest data from the SANTORINI disease registry show that the cardiovascular (CV) risk of hypercholesterolaemia patients was underestimated considerably in the clinical setting.1,2,3 SANTORINI data show that nearly 80% of patients who are at high-risk or very high-risk of CV events do not attain guideline recommended low-density lipoprotein cholesterol (LDL-C) […]
The SANTORINI study highlights that low-density lipoprotein cholesterol (LDL-C) levels remain substantially higher than recommended goals in patients who are at high- and very high-risk of cardiovascular events.1 Study data further demonstrate that combination therapies are being under-utilised, with nearly 73% of these patients not receiving combination therapy, despite their […]
Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional […]
NILEMDO®▼ (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers Low-Density Lipoprotein Cholesterol (LDL-C) and can be combined with other treatments to help lower cholesterol even further1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering […]
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol and can be combined with other treatments to help lower cholesterol even further1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to […]
Bempedoic acid is being developed as a first-in-class, affordable, oral treatment which lowers low-density lipoprotein cholesterol (LDL-C), and which can be combined with other oral treatments to help lower cholesterol even further1,2,3,4,5 Data from Phase 2 study show a 40% reduction in LDL-C for patients with type 2 diabetes who […]
